AI assistant
H. Lundbeck A — Share Issue/Capital Change 2017
Aug 22, 2017
Preview isn't available for this file type.
Download source fileValby, Denmark, 2017-08-22 10:47 CEST (GLOBE NEWSWIRE) -- Valby, Denmark, 22
August 2017 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to
increase its share capital by DKK 2,354,445 as a consequence of the exercise of
employee warrants.
The increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following prices per share of nominally DKK 5: 2,558 shares at DKK 97, 24,203
shares at DKK 113, 3,332 shares at DKK 121 and 440,796 shares at DKK 156.16.
Proceeds to the company are DKK 72,220,940 (approximately USD 11.4 million).
The increase corresponds to approximately 0.2373 % of the company's share
capital.
The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares shall give rights to
dividends and other rights in relation to the company from the time of
registration of the capital increase. The new shares will be listed on NASDAQ
OMX Copenhagen after registration with the Danish Business Authority.
Lundbeck's current share capital amounts to DKK 992,302,945. The capital
increase is expected to be finalized shortly and the total number of voting
rights and the total share capital will after the capital increase be:
Number of shares Nominal value of shares Number of votes
(nominal value DKK 5) (DKK)
198,931,478 994,657,390 198,931,478
Lundbeck contacts
Investors: Media:
Palle Holm Olesen Mads Kronborg
Vice President, Investor Relations Senior Director, Corp. Communication
[email protected] [email protected]
+45 30 83 24 26 +45 36 43 40 00
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company
specialized in psychiatric and neurological disorders. For more than 70 years,
we have been at the forefront of research within neuroscience. Our key areas of
focus are Alzheimer's disease, depression, Parkinson's disease and
schizophrenia.
Our approximately 5,000 employees in 55 countries are engaged in the entire
value chain throughout research, development, manufacturing, marketing and
sales. Our pipeline consists of several late-stage development programmes and
our products are available in more than 100 countries. We have production
facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 15.6
billion in 2016 (EUR 2.1 billion; USD 2.2 billion).
For additional information, we encourage you to visit our corporate site
www.lundbeck.com and connect with us on Twitter at @Lundbeck.
Safe Harbor/Forward-Looking Statements
The above information contains forward-looking statements that provide our
expectations or forecasts of future events such as new product introductions,
product approvals and financial performance.
Such forward-looking statements are subject to risks, uncertainties and
inaccurate assumptions. This may cause actual results to differ materially from
expectations and it may cause any or all of our forward-looking statements here
or in other publications to be wrong. Factors that may affect future results
include interest rate and currency exchange rate fluctuations, delay or failure
of development projects, production problems, unexpected contract breaches or
terminations, government-mandated or market-driven price decreases for
Lundbeck's products, introduction of competing products, Lundbeck's ability to
successfully market both new and existing products, exposure to product
liability and other lawsuits, changes in reimbursement rules and governmental
laws and related interpretation thereof, and unexpected growth in costs and
expenses.
Certain assumptions made by Lundbeck are required by Danish Securities Law for
full disclosure of material corporate information. Some assumptions, including
assumptions relating to sales associated with product that is prescribed for
unapproved uses, are made taking into account past performances of other
similar drugs for similar disease states or past performance of the same drug
in other regions where the product is currently marketed. It is important to
note that although physicians may, as part of their freedom to practice
medicine in the US, prescribe approved drugs for any use they deem appropriate,
including unapproved uses, at Lundbeck, promotion of unapproved uses is
strictly prohibited.